» Articles » PMID: 9632756

Activation of C-myc Gene Expression by Tumor-derived P53 Mutants Requires a Discrete C-terminal Domain

Overview
Journal Mol Cell Biol
Specialty Cell Biology
Date 1998 Jun 25
PMID 9632756
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

Mutation of the p53 tumor suppressor gene is the most common genetic alteration in human cancer, and tumors that express mutant p53 may be more aggressive and have a worse prognosis than p53-null cancers. Mutant p53 enhances tumorigenicity in the absence of a transdominant negative mechanism, and this tumor-promoting activity correlates with its ability to transactivate reporter genes in transient transfection assays. However, the mechanism by which mutant p53 functions in transactivation and its endogenous cellular targets that promote tumorigenicity are unknown. Here we report that (i) mutant p53 can regulate the expression of the endogenous c-myc gene and is a potent activator of the c-myc promoter; (ii) the region of mutant p53 responsiveness in the c-myc gene has been mapped to the 3' end of exon 1; (iii) the mutant p53 response region is position and orientation dependent and therefore does not function as an enhancer; and (iv) transactivation by mutant p53 requires the C terminus, which is not essential for wild-type p53 transactivation. These data suggest that it may be possible to selectively inhibit mutant p53 gain of function and consequently reduce the tumorigenic potential of cancer cells. A possible mechanism for transactivation of the c-myc gene by mutant p53 is proposed.

Citing Articles

Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells.

Tang M, Crown J, Duffy M Invest New Drugs. 2023; 41(4):541-550.

PMID: 37233863 PMC: 10447602. DOI: 10.1007/s10637-023-01368-1.


Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification.

Lin X, Lin X, Guo L, Wang Y, Zhang G Thorac Cancer. 2022; 13(24):3441-3450.

PMID: 36305094 PMC: 9750818. DOI: 10.1111/1759-7714.14703.


c-Myc Sustains Pancreatic Cancer Cell Survival and mutp53 Stability through the Mevalonate Pathway.

Romeo M, Gilardini Montani M, Arena A, Benedetti R, DOrazi G, Cirone M Biomedicines. 2022; 10(10).

PMID: 36289751 PMC: 9599358. DOI: 10.3390/biomedicines10102489.


Identification and validation of the role of c-Myc in head and neck squamous cell carcinoma.

Zhao S, An L, Yang X, Wei Z, Zhang H, Wang Y Front Oncol. 2022; 12:820587.

PMID: 36119473 PMC: 9470836. DOI: 10.3389/fonc.2022.820587.


Role of Dietary Antioxidants in p53-Mediated Cancer Chemoprevention and Tumor Suppression.

Merlin J, Rupasinghe H, Dellaire G, Murphy K Oxid Med Cell Longev. 2021; 2021:9924328.

PMID: 34257824 PMC: 8257365. DOI: 10.1155/2021/9924328.


References
1.
Lill N, Grossman S, Ginsberg D, DeCaprio J, Livingston D . Binding and modulation of p53 by p300/CBP coactivators. Nature. 1997; 387(6635):823-7. DOI: 10.1038/42981. View

2.
Gu W, Shi X, Roeder R . Synergistic activation of transcription by CBP and p53. Nature. 1997; 387(6635):819-23. DOI: 10.1038/42972. View

3.
Bentley D, Groudine M . A block to elongation is largely responsible for decreased transcription of c-myc in differentiated HL60 cells. Nature. 1986; 321(6071):702-6. DOI: 10.1038/321702a0. View

4.
NEPVEU A, Marcu K . Intragenic pausing and anti-sense transcription within the murine c-myc locus. EMBO J. 1986; 5(11):2859-65. PMC: 1167235. DOI: 10.1002/j.1460-2075.1986.tb04580.x. View

5.
Masuda H, Miller C, Koeffler H, Battifora H, Cline M . Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci U S A. 1987; 84(21):7716-9. PMC: 299371. DOI: 10.1073/pnas.84.21.7716. View